UBS O'Connor’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-1,162,096
| Closed | -$1M | – | 447 |
|
|
2019
Q4 | $1M | Hold |
1,162,096
| – | – | 0.03% | 223 |
|
|
2019
Q3 | $657K | Hold |
1,162,096
| – | – | 0.02% | 225 |
|
|
2019
Q2 | $604K | Hold |
1,162,096
| – | – | 0.01% | 192 |
|
|
2019
Q1 | $529K | Hold |
1,162,096
| – | – | 0.01% | 198 |
|
|
2018
Q4 | $558K | Hold |
1,162,096
| – | – | 0.02% | 192 |
|
|
2018
Q3 | $616K | Hold |
1,162,096
| – | – | 0.01% | 227 |
|
|
2018
Q2 | $581K | Buy |
1,162,096
+1,445
| +0.1% | +$673 | 0.01% | 231 |
|
|
2018
Q1 | $490K | Sell |
1,160,651
-77,426
| -6% | -$31.1K | 0.01% | 264 |
|
|
2017
Q4 | $470K | Hold |
1,238,077
| – | – | 0.01% | 263 |
|
|
2017
Q3 | $446K | Hold |
1,238,077
| – | – | 0.01% | 304 |
|
|
2017
Q2 | $470K | Hold |
1,238,077
| – | – | 0.01% | 341 |
|
|
2017
Q1 | $557K | Hold |
1,238,077
| – | – | 0.01% | 359 |
|
|
2016
Q4 | $470K | Hold |
1,238,077
| – | – | 0.01% | 361 |
|
|
2016
Q3 | $334K | Hold |
1,238,077
| – | – | 0.01% | 382 |
|
|
2016
Q2 | $297K | Sell |
1,238,077
-1,128,557
| -48% | -$194K | 0.01% | 360 |
|
|
2016
Q1 | $270K | Sell |
2,366,634
-54,823
| -2% | -$5.94K | ﹤0.01% | 401 |
|
|
2015
Q4 | $272K | Hold |
2,421,457
| – | – | ﹤0.01% | 400 |
|
|
2015
Q3 | $461K | Buy |
2,421,457
+6,619
| +0.3% | +$2.25K | ﹤0.01% | 463 |
|
|
2015
Q2 | $1.69M | Hold |
2,414,838
| – | – | 0.01% | 459 |
|
|
2015
Q1 | $1.64M | Buy |
2,414,838
+1,211,660
| +101% | +$847K | 0.02% | 449 |
|
|
2014
Q4 | $944K | Hold |
1,203,178
| – | – | 0.02% | 360 |
|
|
2014
Q3 | $559K | Hold |
1,203,178
| – | – | 0.01% | 376 |
|
|
2014
Q2 | $602K | Hold |
1,203,178
| – | – | ﹤0.01% | 362 |
|
|
2014
Q1 | $373K | Hold |
1,203,178
| – | – | 0.01% | 371 |
|
|
2013
Q4 | $409K | Hold |
1,203,178
| – | – | 0.01% | 331 |
|
|
2013
Q3 | $2.43M | Sell |
1,203,178
-11,847
| -1% | -$22.6K | 0.05% | 261 |
|
|
2013
Q2 | $2.31M | Buy |
+1,215,025
| New | +$2.13M | 0.04% | 314 |
|
UBS O'Connor's GCVRZ Position: Q1 2020 in Review
UBS O'Connor sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 1,162,096 shares — an estimated $1M sold.
UBS O'Connor first reported a position in GCVRZ in Q2 2013 and held it in 27 quarters. The position peaked at $2.43M in Q3 2013. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- UBS O'Connor reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- UBS O'Connor sold 1,162,096 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $1M.
- UBS O'Connor first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 27 quarters.
- UBS O'Connor's Sanofi Contingent Value Rights position peaked at $2.43M in Q3 2013.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on UBS O'Connor's 13F filing for Q1 2020, filed 15 May 2020.